Compare OCGN & OFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCGN | OFIX |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.8M | 473.3M |
| IPO Year | 2014 | 1998 |
| Metric | OCGN | OFIX |
|---|---|---|
| Price | $1.50 | $11.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.75 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 9.3M | 417.1K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.58 | 29.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $822,312,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | $1,718.38 | $6.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.85 |
| 52 Week Low | $0.93 | $8.85 |
| 52 Week High | $2.73 | $16.99 |
| Indicator | OCGN | OFIX |
|---|---|---|
| Relative Strength Index (RSI) | 56.09 | 66.88 |
| Support Level | $1.32 | $11.24 |
| Resistance Level | $1.58 | $12.72 |
| Average True Range (ATR) | 0.10 | 0.57 |
| MACD | 0.03 | 0.33 |
| Stochastic Oscillator | 62.28 | 89.94 |
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.